Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

ClinicalTrials.gov ID: NCT06079671

Public ClinicalTrials.gov record NCT06079671. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

Study identification

NCT ID: NCT06079671
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 800 participants

Conditions and interventions

Conditions

Locally Advanced Cervical Cancer

Interventions

Volrustomig Biological
Placebo Other

Biological · Other

Eligibility (public fields only)

Age range: 15 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 21, 2023
Primary completion: Nov 25, 2027
Completion: Sep 29, 2030
Last update posted: Aug 24, 2026

2023 – 2030

United States locations

U.S. sites: 28
U.S. states: 15
U.S. cities: 27

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35233	Withdrawn
Research Site	Phoenix	Arizona	85016	Withdrawn
Research Site	Tucson	Arizona	85711	Withdrawn
Research Site	Little Rock	Arkansas	72205	Withdrawn
Research Site	La Jolla	California	92093	Withdrawn
Research Site	West Hollywood	California	90048	Withdrawn
Research Site	Atlanta	Georgia	30322	Withdrawn
Research Site	Augusta	Georgia	30912	Withdrawn
Research Site	Savannah	Georgia	31405	Terminated
Research Site	Melrose Park	Illinois	60160	Withdrawn
Research Site	Indianapolis	Indiana	46202	Withdrawn
Research Site	New Orleans	Louisiana	70112	Withdrawn
Research Site	New Orleans	Louisiana	70121	Withdrawn
Research Site	Shreveport	Louisiana	71103	Completed
Research Site	New York	New York	10016	Withdrawn
Research Site	Syracuse	New York	13210	Withdrawn
Research Site	Cleveland	Ohio	44195	Withdrawn
Research Site	Columbus	Ohio	43210	Withdrawn
Research Site	Eugene	Oregon	97401	Withdrawn
Research Site	Philadelphia	Pennsylvania	19107	Withdrawn
Research Site	Providence	Rhode Island	02905	Withdrawn
Research Site	Dallas	Texas	75390	Withdrawn
Research Site	Fort Worth	Texas	76104	Terminated
Research Site	Houston	Texas	77030	Withdrawn
Research Site	Tyler	Texas	75702	Withdrawn
Research Site	Charlottesville	Virginia	22908	Completed
Research Site	Fairfax	Virginia	22031	Withdrawn
Research Site	Richmond	Virginia	23298	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 177 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06079671, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06079671 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →